文献速递肝病

全血体外系统联合HLA敲除肝类器官与粒细胞-单核细胞吸附逆转ACLF和ALF

Reversal of ACLF and ALF using whole blood extracorporeal system combining HLA-depleted liver organoids with granulocyte-monocyte apheresis.
PubMed 文献 · J Hepatol · 2025-10-02

本研究设计UTOPiA体外循环系统,将粒细胞-单核细胞吸附(GMA)与HLA-A、HLA-B、CIITA三敲除的人诱导多能干细胞来源肝细胞样细胞(iHLC)类器官串联,经静脉全血暴露用于ACLF和ALF大鼠模型。UTOPiA显著改善两种模型生存,优于GMA或iHLC单药及基于HepG2细胞的装置,并减轻昏迷、改善肝功能、降低高氨血症、高胆红素血症和全身炎症。

要点

  • UTOPiA串联GMA与HLA三敲除iHLC类器官,经全血暴露治疗ACLF/ALF大鼠。
  • UTOPiA生存获益优于GMA或iHLC单药及HepG2细胞装置。
  • 机制涉及iHLC分泌AFP经p21下调促肝再生,并恢复HNF4α、降低IL-6和TNF-α。

核心结论

  • UTOPiA串联体外循环在ACLF和ALF临床前大鼠模型中提供显著生存获益,兼具抗炎、合成与代谢支持。

研究设计与样本

  • 设计整合式体外循环UTOPiA系统,串联粒细胞-单核细胞吸附(GMA)与HLA-A、HLA-B、CIITA三敲除的人iPSC来源肝细胞样细胞(iHLC)类器官。
  • 在大鼠ACLF和ALF模型中经静脉血流直接全血暴露后测试UTOPiA疗效。

主要发现

  • UTOPiA治疗显著改善ACLF和ALF大鼠模型生存,优于GMA或iHLC单药及基于HepG2细胞的装置。
  • 生存改善伴随昏迷严重度降低、肝功能生化改善以及高氨血症、高胆红素血症和全身炎症减轻。
  • 转录组和组织学分析显示肝脏代谢基因表达恢复和肝细胞再生。
  • 机制上,iHLC分泌的α-胎儿蛋白通过下调p21抑制肝细胞细胞周期阻滞并增强再生,UTOPiA恢复HNF4α活性并抑制包括IL-6和TNF-α在内的促炎细胞因子。

临床怎么用

  • 该全血体外系统作为即用型肝支持疗法,可能为危及生命的肝衰竭患者提供同时控制炎症、恢复肝功能并促进再生的治疗选择。

局限性

  • 疗效仅在临床前啮齿类动物模型中验证,尚未在人体中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is characterized by catastrophic loss of liver function in patients with advanced chronic liver disease, with 28-day mortality rates reaching up to 80%. Despite advances in intensive care, the high mortality primarily stems from the absence of a therapeutic modality that simultaneously addresses both the profound systemic inflammatory response and severe hepatic synthetic dysfunction. METHODS: We designed an integrated extracorporeal circuit, termed the UTOpiA system, which combines granulocyte and monocyte apheresis (GMA) with human induced pluripotent stem cell-derived hepatocyte-like cell (iHLC) organoids engineered with HLA-A, HLA-B, and CIITA triple knockout. The efficacy of UTOpiA was tested after direct whole blood exposure through venous flow in rat models of ACLF and acute liver failure (ALF). RESULTS: UTOpiA treatment significantly improved survival in both ACLF and ALF rat models, outperforming GMA or iHLC monotherapy and HepG2 cell-based devices. Improved survival was associated with reduced coma severity, improved liver biochemistry, and reduced hyperammonaemia, hyperbilirubinemia, and systemic inflammation. Transcriptomic and histological analyses revealed restoration of hepatic metabolic gene expression and hepatocyte regeneration. Mechanistically, iHLC-secreted α-fetoprotein suppressed hepatocyte cell cycle arrest via p21 downregulation and enhanced regeneration, while UTOpiA restored HNF4α activity and dampened pro-inflammatory cytokines, including IL-6 and TNF-α. CONCLUSIONS: The tandem UTOpiA circuit confers a significant survival benefit in preclinical rodent models of ACLF and ALF by providing anti-inflammatory, synthetic, and metabolic support. Elucidating the regenerative signals that promote recovery of the injured liver may further expand the potential of this whole blood extracorporeal system as a novel, off-the-shelf liver support therapy. IMPACT AND IMPLICATIONS: Restoring hepatic metabolism while controlling inflammation in acutely decompensated cirrhosis remains a major unmet clinical need. By combining HLA-modified human induced pluripotent stem cell-derived liver organoids with granulocyte and monocyte apheresis, we developed a bioartificial liver system that manages inflammation, restores liver function, and promotes regeneration in two rat models of severe liver failure. This therapy could offer an off-the-shelf treatment option for patients with life-threatening liver failure.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yamaguchi H, Yoneyama Y, Ichimura K, et al. Reversal of ACLF and ALF using whole blood extracorporeal system combining HLA-depleted liver organoids with granulocyte-monocyte apheresis. J Hepatol. 2025. PMID: 41044028. doi:10.1016/j.jhep.2025.08.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。